Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 6/20 | 0.48 |
| ▸ | PLG | P00747 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 9/20 | 0.43 |
| ▸ | FLT1 | P17948 | 8/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18939270 | 0.92 | PLAU (0.46) | PLAUPLGKDRFLT1SLC22A12 | |
| SCHEMBL18960810 | 0.85 | KDR (0.42) | PLAUKDRFLT1SLC22A12 | |
| SCHEMBL18951992 | 0.84 | KDR (0.45) | PLAUKDRFLT1SLC22A12 | |
| Hydrochloric Acid SCHEMBL18939075 | 0.84 | KDR (0.41) | PLAUKDRFLT1SLC22A12 | |
| SCHEMBL28651087 | 0.81 | KDR (0.51) | KDRFLT1SLC22A12 | |
| SCHEMBL18967498 | 0.80 | SLC22A12 (0.39) | PLAUKDRFLT1SLC22A12 | |
| SCHEMBL18960812 | 0.79 | FLT1 (0.41) | KDRFLT1SLC22A12 | |
| SCHEMBL18960819 | 0.79 | SLC22A12 (0.38) | PLAUPLGKDRFLT1SLC22A12 | |
| SCHEMBL18939015 | 0.78 | PLAU (0.41) | PLAUPLGSLC22A12 | |
| SCHEMBL18939084 | 0.78 | KDR (0.42) | KDRFLT1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108463461-B | Cephem compounds, their preparation and use | 奈加-RGM制药有限公司 | 2021-11-19 | — | — | CN | disclosed |
| US-RE48097-E1 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2020-07-14 | — | — | US | disclosed |
| US-RE48097-E1 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2020-07-14 | — | — | US | disclosed |
| EP-3386977-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM Pharmaceuticals ULC (CA) | 2018-10-17 | — | — | EP | disclosed |
| US-9751894-B2 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-09-05 | — | — | US | disclosed |
| US-9751894-B2 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-09-05 | — | — | US | disclosed |
| US-9751894-B2 | Cephem compounds, their production and use | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-09-05 | — | — | US | disclosed |
| WO-2017096472-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS INC. (CA) | 2017-06-15 | — | — | WO | disclosed |
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2017-06-15 | — | — | US | disclosed |
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2017-06-15 | — | — | US | disclosed |
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | NAEJA-RGM PHARMACEUTICALS ULC (CA) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166587-A1 | CEPHEM COMPOUNDS, THEIR PRODUCTION AND USE | CEP170, AADAC, NAA50 | PLAU 4395/4885PLG 3373/4885KDR 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.